{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:02:35Z","timestamp":1790661755129,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"11-12","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lpm.2018.10.009","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T12:36:10Z","timestamp":1541507770000},"page":"e253-e259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"P2","title":["Neuromuscular complications of immune checkpoint inhibitors"],"prefix":"10.1016","volume":"47","author":[{"given":"Dimitri","family":"Psimaras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2018.10.009_bib0350","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.lpm.2018.10.009_bib0355","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0365","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2018.10.009_bib0370","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2018.10.009_bib0375","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.lpm.2018.10.009_bib0385","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0390","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CMR.0000000000000314","article-title":"New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma","volume":"27","author":"Behling","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.lpm.2018.10.009_bib0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2018.01.030","article-title":"Nivolumab-induced myositis: a case report and a literature review","volume":"387","author":"Bourgeois-Vionnet","year":"2018","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.lpm.2018.10.009_bib0400","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.lpm.2018.10.009_bib0405","article-title":"A case of nivolumab-induced myositis","volume":"12","author":"Fox","year":"2016","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.lpm.2018.10.009_bib0410","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2018.10.009_bib0415","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.lpm.2018.10.009_bib0420","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","author":"Shah","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2018.10.009_bib0430","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdw126","article-title":"Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma","volume":"27","author":"Vallet","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.lpm.2018.10.009_bib0435","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12991","article-title":"Case of respiratory discomfort due to myositis after administration of nivolumab","volume":"42","author":"Yoshioka","year":"2015","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2018.10.009_bib0440","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.mayocp.2016.12.025","article-title":"Diagnosis and management of immune-mediated myopathies","volume":"92","author":"Milone","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.lpm.2018.10.009_bib0445","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0450","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.lpm.2018.10.009_bib0455","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.lpm.2018.10.009_bib0460","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0470","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0475","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"issue":"33","key":"10.1016\/j.lpm.2018.10.009_bib0480","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0485","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.lpm.2018.10.009_bib0490","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lpm.2018.10.009_bib0495","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0500","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JND-170219","article-title":"Severe exacerbation of myasthenia gravis associated with checkpoint inhibitor immunotherapy","volume":"4","author":"Cooper","year":"2017","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.lpm.2018.10.009_bib0505","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci"},{"issue":"4","key":"10.1016\/j.lpm.2018.10.009_bib0510","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1002\/mus.26021","article-title":"Refractory myasthenia gravis exacerbation triggered By pembrolizumab","volume":"57","author":"Earl","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0515","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0520","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0525","article-title":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases","volume":"4","author":"Phadke","year":"2016","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.lpm.2018.10.009_bib0530","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0535","doi-asserted-by":"crossref","first-page":"055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.lpm.2018.10.009_bib0540","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2018.10.009_bib0545","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0550","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.lpm.2018.10.009_bib0555","first-page":"e1702","article-title":"Myasthenia gravis induced by nivolumab: a case report","volume":"9","author":"Mehta","year":"2017","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.lpm.2018.10.009_bib0560","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0565","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.lpm.2018.10.009_bib0570","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3988\/jcn.2018.14.1.115","article-title":"Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer","volume":"14","author":"Huh","year":"2018","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0575","doi-asserted-by":"crossref","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lpm.2018.10.009_bib0580","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.lpm.2018.10.009_bib0585","doi-asserted-by":"crossref","first-page":"e00355","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino","year":"2018","journal-title":"Respirol Case Rep"},{"issue":"5","key":"10.1016\/j.lpm.2018.10.009_bib0590","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol"},{"issue":"11","key":"10.1016\/j.lpm.2018.10.009_bib0595","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"62","key":"10.1016\/j.lpm.2018.10.009_bib0600","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1515584","article-title":"Pembrolizumab-induced demyelinating polyradiculoneuropathy","volume":"375","author":"de Maleissye","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.10.009_bib0605","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","article-title":"Immune mediated neuropathy following checkpoint immunotherapy","volume":"45","author":"Gu","year":"2017","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.lpm.2018.10.009_bib0610","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jns.2018.04.028","article-title":"Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barr\u00e9 syndrome","volume":"390","author":"Nukui","year":"2018","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.lpm.2018.10.009_bib0615","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/mus.25663","article-title":"Facial diplegia after pembrolizumab treatment","volume":"56","author":"Yost","year":"2017","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.lpm.2018.10.009_bib0620","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced guillain-barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced, colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.lpm.2018.10.009_bib0625","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26101","article-title":"Guillain-Barr\u00e9-like syndrome during pembrolizumab treatment","author":"Ong","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lpm.2018.10.009_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2018.1485912","article-title":"Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?","volume":"22","author":"Barp","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.lpm.2018.10.009_bib0635","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol"},{"issue":"4","key":"10.1016\/j.lpm.2018.10.009_bib0640","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp-2017-316510","article-title":"Acute demyelinating Polyneuropathy induced by nivolumab","volume":"89","author":"Fukumoto","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.lpm.2018.10.009_bib0645","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00432-016-2191-7","article-title":"A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use","volume":"142","author":"Jacob","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2018.10.009_bib0650","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-2548","article-title":"PD-1 Antibody-induced guillain-barr\u00e9 syndrome in a patient with metastatic melanoma","volume":"97","author":"Schneiderbauer","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0655","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.lpm.2018.10.009_bib0660","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain\u2013Barr\u00e9 syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0665","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WNO.0000000000000217","article-title":"Ipilimumab-associated bilateral optic neuropathy","volume":"35","author":"Yeh","year":"2015","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.lpm.2018.10.009_bib0670","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","article-title":"Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy","volume":"83","author":"Boisseau","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.lpm.2018.10.009_bib0675","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jjco\/hyw090","article-title":"Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barr\u00e9 syndrome: a case report","volume":"46","author":"Tanaka","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.lpm.2018.10.009_bib0685","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.lpm.2018.10.009_bib0690","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218303877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218303877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:22:32Z","timestamp":1662376952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498218303877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":68,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0755498218303877"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2018.10.009","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromuscular complications of immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}